Summary by Futu AI
Invivyd announced that its COVID-19 antibody PEMGARDA (pemivibart) maintains consistent neutralization potency against contemporary variants KP.3.1.1 and LB.1, aligning with results from predominant variants since 2022. The company's ongoing structural analysis reveals sustained stability of the pemivibart binding site since late 2021's Omicron emergence.Independent testing through LabCorp's Monogram Biosciences lab demonstrates that PEMGARDA's effectiveness remains stable across a wide range of SARS-CoV-2 variants. The binding site analysis, focusing on 19 key amino acids within 5 angstroms of the spike protein interaction, shows minimal mutational changes, supporting expectations for continued neutralization activity.The company's analysis suggests that potential emerging variants XEC and LP.1, whose mutations are distant from the pemivibart binding site, are unlikely to significantly affect PEMGARDA's activity. Routine neutralization testing will continue to monitor for any potential impacts from epistasis or allostery.
